Maria Jure-Kunkel

Years Active: 2021-2022
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Alexander Muik, Elena Garralda, Isil Altintas, Friederike Gieseke, Ravit Geva, Eytan Ben-Ami, Corinne Maurice-Dror, Emiliano Calvo, Patricia M LoRusso, Guzman Alonso, Maria E Rodriguez-Ruiz, Kristina B Schoedel, Jordan M Blum, Bianca Sänger, Theodora W Salcedo, Saskia M Burm, Eliana Stanganello, Dennis Verzijl, Fulvia Vascotto, Angelica Sette, Juliane Quinkhardt, Theo S Plantinga, Aras Toker, Edward N van den Brink, Mark Fereshteh, Mustafa Diken, David Satijn, Sebastian Kreiter, Esther C W Breij, Gaurav Bajaj, Eleni Lagkadinou, Kate Sasser, Özlem Türeci, Ulf Forssmann, Tahamtan Ahmadi, Uğur Şahin, Maria Jure-Kunkel, Ignacio Melero Bermejo
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer discovery 12 (5) (2022)
Nabendu Pore, Song Wu, Nathan Standifer, Maria Jure-Kunkel, Melissa de Los Reyes, Yashaswi Shrestha, Rebecca Halpin, Raymond Rothstein, Kathy Mulgrew, Stephen Blackmore, Philip Martin, John Meekin, Matthew Griffin, Ina Bisha, Theresa A Proia, Ricardo J Miragaia, Ronald Herbst, Ashok Gupta, Shaad E Abdullah, Rajiv Raja, Melanie M Frigault, J Carl Barrett, Phillip A Dennis, Maria Libera Ascierto, Michael D Oberst
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown. Cancer discovery 11 (11) (2021)

Maria Jure-Kunkel.css-eqlu8i{font-size:small;padding-left:4px;}